All | LR+RT+ | LR-RT+ | |
---|---|---|---|
Time to local recurrence, months | n = 30 | n = 47 | |
Median | |||
Range | 50 | - | |
Follow-up, months | 8–149 | - | |
Median | |||
Range | - | 85 | |
Tamoxifen | - | 62–231 | |
Chemotherapy | 6 | 1 | |
Tamoxifen and chemotherapy | 0 | 0 | |
No adjuvant treatment | 0 | 0 | |
24 | 46 | ||
Inclusion 1 and 2 | Inclusion 1 | Inclusion 2 | Inclusion 1 |
Menopause | |||
Pre | 12 | 5 | 13 |
Post | 7 | 1 | 33 |
Not available | 0 | 5 | 1 |
Age at operation, years | |||
Median | 48 | 47 | 57 |
Range | 27–63 | 34–73 | 33–73 |
Size, millimeters | |||
Median | 14 | 15 | 15 |
Range | 2–32 | 10–20 | 4–22 |
Not available | 0 | 2a | 0 |
Grade | |||
1 | 3 | 3 | 22 |
2 | 8 | 6 | 13 |
3 | 7 | 1 | 10 |
Not available | 1 | 1 | 2 |
Estrogen receptor | |||
Positive | 9 | 11 | 42 |
Negative | 10 | 0 | 5 |
Progesterone receptor | |||
Positive | 5 | 9 | 31 |
Negative | 13 | 2 | 11 |
Not available | 1 | 0 | 5 |
Health care region | |||
South | 8 | 2 | 30 |
West | 2 | 0 | 9 |
South-East | 0 | 9 | 0 |
Stockholm | 9 | 0 | 8 |